A new drug for treating severe alopecia has been approved in the UK. The drug showed good results in hair restoration during clinical trials.
MHRA approval of the drug
British medicines regulator MHRA approved deuruxolitinib, also known as Leqselvi, for the treatment of people with severe focal alopecia. This solution opens up new opportunities for patients suffering from hair loss.
The drug was positively evaluated after analysing the results of clinical trials that demonstrated its effectiveness in the fight against alopecia.
Results of clinical trials
In clinical trials, almost a third of patients regained at least 80% of scalp hair over six months of treatment. This indicates significant progress in the treatment of severe alopecia.
Deuruxolitinib works by reducing inflammation and blocking damage to hair follicles by the immune system. This allows the hair to grow back.
Ukrainian
English
